GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Aroa Biosurgery Ltd (ASX:ARX) » Definitions » Retained Earnings

Aroa Biosurgery (ASX:ARX) Retained Earnings : A$-57.02 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aroa Biosurgery Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Aroa Biosurgery's retained earnings for the quarter that ended in Mar. 2024 was A$-57.02 Mil.

Aroa Biosurgery's quarterly retained earnings declined from Mar. 2023 (A$-48.23 Mil) to Sep. 2023 (A$-53.73 Mil) and declined from Sep. 2023 (A$-53.73 Mil) to Mar. 2024 (A$-57.02 Mil).

Aroa Biosurgery's annual retained earnings declined from Mar. 2022 (A$-47.52 Mil) to Mar. 2023 (A$-48.23 Mil) and declined from Mar. 2023 (A$-48.23 Mil) to Mar. 2024 (A$-57.02 Mil).


Aroa Biosurgery Retained Earnings Historical Data

The historical data trend for Aroa Biosurgery's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aroa Biosurgery Retained Earnings Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24
Retained Earnings
-32.66 -39.24 -47.52 -48.23 -57.02

Aroa Biosurgery Semi-Annual Data
Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24
Retained Earnings Get a 7-Day Free Trial -47.52 -43.60 -48.23 -53.73 -57.02

Aroa Biosurgery Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Aroa Biosurgery  (ASX:ARX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Aroa Biosurgery (ASX:ARX) Business Description

Traded in Other Exchanges
N/A
Address
64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company which develops, manufactures and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The Company is in the business of developing, manufacturing and selling soft tissue repair products. The company's principal market is the United States where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery and trauma/limb salvage/tumor surgery.

Aroa Biosurgery (ASX:ARX) Headlines

No Headlines